Fig. 9.

The GLP-1 agonist liraglutide and the GLP-2 agonist teduglutide reduced hepatic analyte levels (A–C) and improved hepatic characteristics (D–F) in mice fed an HFCD (a model of nonalcoholic fatty liver disease and mild Type 2 diabetes). Data are expressed as means ± SE (n = 10 per group). Statistical analyses were performed using one-way ANOVA followed by Holm-Šídák’s multiple-comparisons test. *P < 0.05, **P < 0.01, and ****P < 0.0001 vs. vehicle-HFCD-fed group. ALT, alanine aminotransferase; AST, aspartate aminotransferase; GLP, glucagon-like peptide; HFCD, high fat, cholesterol, and carbohydrate diet; IU, international units; ND, normal diet; sc, subcutaneous.